Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02041325|
Recruitment Status : Completed
First Posted : January 22, 2014
Results First Posted : May 17, 2016
Last Update Posted : May 17, 2016
Boston VA Research Institute, Inc.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Nikhil Munshi, M.D., Boston VA Research Institute, Inc.
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator)|
Plasma Cell Disorder